OncoMax’s renal cell carcinoma research awarded special prize in Europe
10 Dec '13
Extensive research conducted by Russian company OncoMax in the field of cancer therapy was honored with a special First Prize award last month at the 5th European Multidisciplinary Meeting for Urological Cancer (EMUC), announced the official website of Russian Venture Company (RVC), Russia’s fund of funds for innovation whose subsidiary participated in OncoMax’es first round of funding three years ago.
The research is said to have proven that using the OM-RCA-01, a monoclonal antibody developed most recently by OncoMax and capable of blocking the FGF receptor, can inhibit blood vessel growth in a kidney tumor.
“This elegant study has a great practical importance and answers the question how to overcome drug resistance in kidney cancer therapy,” emphasized Dr. Martin Spahn, the co-chairman of the Organizing Committee, during the award presentation.
EMUC is an annual meeting organized by three European medical societies , including the European Society for Medical Oncology (ESMO), the European Association of Urology (EAU), and the European Society for Radiotherapy and Oncology (ESTRO). Held on November, 15-17 in Marseille, France, this year’s event brought together experts, clinical researchers and other professionals in the treatment of kidney cancer, bladder cancer, and prostate cancer.
OncoMax is a private biotechnology company founded in 2010 with the goal to develop and launch new diagnostic and therapeutic anti-cancer agents, including the above drug to fight renal cell carcinoma.
COMMENT ON THIS STORY
Find Related Content
Tags:OncoMax (5) / OM RCA 01 (0) / Martin Spahn (0) / EMUC 2013 (0) /